Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-09-21), BioInvent International AB's 3-1 Month Momentum % is 0.65%.
The industry rank for BioInvent International AB's 3-1 Month Momentum % or its related term are showing as below:
LTS:0H22's 3-1 Month Momentum % is ranked better than 52.46% of 1382
companies
in the Biotechnology industry
Industry Median: 0.36
vs LTS:0H22: 0.65
BioInvent International AB (LTS:0H22) 3-1 Month Momentum % Explanation
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
BioInvent International AB 3-1 Month Momentum % Related Terms
LTS:0H22 vs VRTX, REGN, MRNA: 3-1 Month Momentum % Comparison
For the Biotechnology subindustry, BioInvent International AB's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioInvent International AB 3-1 Month Momentum % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, BioInvent International AB's 3-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where BioInvent International AB's 3-1 Month Momentum % falls into.
BioInvent International AB (LTS:0H22) 3-1 Month Momentum % Calculation
3-1 Month Momentum % is calculated as following:
3-1 Month Momentum %
=
( Price 1-month ago
/
Price 3-month ago
- 1 )
*
100 %
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BioInvent International AB (LTS:0H22) has a 3-1 Month Momentum % of 0.65% as of Sep. 21, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on BioInvent International AB and its competitors. According to the industry distribution chart, BioInvent International AB ranks #657 out of 1382 companies in the Biotechnology industry, placing it in the top 47.5%.
Is BioInvent International AB's 3-1 Month Momentum % too high?
BioInvent International AB's current 3-1 Month Momentum % is 0.65%. The Biotechnology industry median 3-1 Month Momentum % is 0.36. BioInvent International AB's value of 0.65% is 80.6% above this industry median. Based on the distribution chart, BioInvent International AB ranks #657 out of 1382 companies in the Biotechnology industry, which is above the industry midpoint. Overall, BioInvent International AB has a GF Score™ of 31/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does BioInvent International AB's 3-1 Month Momentum % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, BioInvent International AB ranks #657 out of 1382 companies for 3-1 Month Momentum %. This puts BioInvent International AB in the upper half of its industry. The industry median 3-1 Month Momentum % is 0.36. BioInvent International AB's value of 0.65% is 80.6% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Biotechnology company?
The median 3-1 Month Momentum % among Biotechnology companies is 0.36, based on 1,382 companies in the industry. Companies in the top quartile (top 25%) have a 3-1 Month Momentum % significantly above this median, while those in the bottom quartile fall well below. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BioInvent International AB's current 3-1 Month Momentum % of 0.65% is 80.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on BioInvent International AB and its competitors. For the Biotechnology industry, the median 3-1 Month Momentum % is 0.36 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BioInvent International AB's current 3-1 Month Momentum % is 0.65%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioInvent International AB stock overvalued right now?
Based on GuruFocus' analysis, BioInvent International AB (LTS:0H22) is currently considered Significantly Overvalued. The stock's GF Value™ is kr7.52, compared to a current price of kr22.35 — trading 197.2% above its estimated fair value. The current 3-1 Month Momentum % is 0.65% and 80.6% above the Biotechnology industry median of 0.36. BioInvent International AB's overall GF Score™ is 31/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For BioInvent International AB (LTS:0H22), the current 3-1 Month Momentum % is 0.65% as of Sep. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BioInvent International AB (LTS:0H22) Overvalued in 2026?
Based on GuruFocus' analysis, BioInvent International AB stock appears to be overvalued.
The current stock price of kr22.35 is trading 197.2% above its estimated GF Value™ of kr7.52.
GuruFocus considers BioInvent International AB to be Significantly Overvalued.
Key valuation signals for LTS:0H22:
3-1 Month Momentum %: 0.65%
GF Value™: kr7.52 vs. price of kr22.35 (197.2% above fair value)
Industry Position: 80.6% above the Biotechnology median (#657 of 1382)
No single metric tells the full story. See the LTS:0H22 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BioInvent International AB is a clinical-stage biotech company. It discovers and develops novel and first-in-class immuno-modulatory antibodies for cancer therapy, with currently four drug candidates in five ongoing clinical programs in Phase 1/2 trials for the treatment of hematological cancer and solid tumors, respectively. The company's validated, proprietary F.I.R.S.T technology platform identifies both targets and the antibodies that bind to them, generating many new drug candidates to fuel the company's clinical development pipeline and providing licensing and partnering opportunities. The company's pipeline portfolio comprises BI-1206, an antagonistic blocking antibody for the treatment of non-Hodgkin's lymphoma, and BI-1808 and BI-1910 (anti-TNFR2) for solid cancers.
31GF Score
Get the complete analysis for LTS:0H22
3-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0H22 has been successfully added to your 
